149 results about "Glutamine synthetase" patented technology

A method for diagnosing Alzheimer's disease(AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.

The invention relates to an escherichia coli genetically engineered bacterium and a method for efficiently producing L-tryptophan by utilizing the escherichia coli genetically engineered bacterium. The genetically engineered bacterium is obtained by correspondingly transforming and combining L-tryptophan synthesis-related genes in escherichia coli through a metabolic engineering method (includinggene integration, point mutation and promoter substitution) and introducing a glutamine synthetase coding gene glnA from lactobacillus acidophilus on genome of the escherichia coli. The strain is usedfor carrying out shake-flask fermentation; 10 to 12g/L of L-tryptophan can be accumulated within 24 hours, reaches the maximum value reported in China and is improved by 15.1 percent compared with that of an existing L-tryptophan industrial strain carrying plasmid, which shows that the strain has good potential for industrially producing the L-tryptophan.

The invention relates to application of GMFB (glia maturation factor beta) as a biomarker for early diagnosis of diabetic retinopathy and for diabetes progression, application of GMFB as a therapeutic target of diabetic retinopathy, a GMFB disrupter and application of the GMFB disrupter. Compared with the prior art, the invention proves that the GMFB content in vitreous body is significantly improved in early period of diabetes in rats of STZ-induced I type diabetes (TIDM). The invention is the first to prove that GMFB content gradually drops with the development of DR (diabetic retinopathy), therefore the GMFB is applicable to dynamic detection of DR progress; the invention is the first to prove that by interfering GMFB expression in rats of DR, visual function can be protected; and the invention is the first to prove that GMFB mediates retinopathy mechanism, including causing decrease of glutamine synthetase of Muller cell, death of ganglion cells and inducing autophagy of photoreceptor cells.

The invention relates to an ammonia diagnosing/measuring reagent box which utilizes the technique of the enzyme contrasting color method and the enzyme jointing method, and belongs to the technical field of the medicine/food/environment test. The main components of the reagent box of the invention mainly include cushion liquid, coenzyme, glutamic acid, adentosine triphosphoric acid, glyceraldehyde-3-phosphate, glutamine synthetase, glyceraldehyde-3-phosphate dehydrogenase and stabilizing agent; the reagent box generates a series of enzymic reactions through the mixing of the samples and the reagent at a certain cubage rate, and then the reactants are positioned under an ultraviolet/visible light analyzer which tests the reducing speed of the absorbency at the main wave length of 340nm, thereby measuring the concentration size of the enzyme. The invention can absolutely get needed measuring result through the ultraviolet/visible light analyzer.

The invention relates to a glutamine synthetase expression vector which can be amplified and have two expression cassettes. The main components of the glutamine synthetase expression vector include the following six parts: a first expression cassette component, a second expression cassette component, an f1 replicon, a glutamine synthetase expression cassette component, an ampicillin beta lactamase hydrolysis expression cassette component and a ColE1 replicon, wherein a strong enhancer/promotor CMV (Cytomegalovirus) and an immediate early enhancer/promotor are adopted to the first expression cassette component and the second expression cassette component; a weak promotor/enhancer SV40 is adopted to the glutamine synthetase expression cassette component, so that the expression of glutamine synthetase is reduced, and the screening of high-expression cloning is facilitated; and expression protein coding genes are respectively cloned to the expression vector through a multiple cloning site A and a multiple cloning site B. The glutamine synthetase expression vector disclosed by the invention is suitable for simultaneously expressing 1-2 proteins efficiently in mammalian cells and especially suitable for expressing antibody proteins.

Disclosed are a novel expression vector for efficient expression of recombinant proteins in mammalian cells, a mammalian cell transformed with the vector, and a method for production of the mammalian cell. The expression vector includes a gene expression regulatory site, and a gene encoding the protein downstream thereof, and an internal ribosome entry site further downstream thereof, and a gene encoding a glutamine synthetase further downstream thereof.

Methods for the treatment of both diseases susceptible to the inhibition of mammalian glutamine synthetase and progressive hyperammonemic encephalopathy comprising administering L-methionine S-sulfoxime at a dose not to exceed 10 mg/kg body weight are disclosed. Preferably, the dose should not exceed 8 mg/kg; more preferably, the dose should not exceed 5 mg/kg; most preferably, the dose should not exceed 2.5 mg/kg.

The invention is drawn to plant cell transformation with a nucleic acid construct comprising a prokaryotic ammonium-specific asparagine synthetase, type A, coding sequence, operably linked to a chloroplast transit peptide-encoding sequence, wherein said plant cells also contain a nucleic acid construct comprising a chloroplastic glutamine synthetase coding sequence in antisense orientation. Plant cells containing both nucleic acid constructs, and plants regenerated therefrom, exhibit improved growth characteristics.

The invention belongs to the technical field of bioengineering, and discloses corynebacterium glutamicum for high yield of L-glutamine as well as a construction method and an application of corynebacterium glutamicum. The activity of alpha-ketoglutarate dehydrogenase and/or glutamic acid exporter protein in cells of the corynebacterium glutamicum for highly producing L-glutamine is lost, and adenylation modification of glutamine synthetase is removed. According to the corynebacterium glutamicum for highly producing L-glutamine disclosed by the invention, L-glutamine can be accumulated in a culture medium or cells, so that the yield of L-glutamine is increased to a great extent. The experiments show that the corynebacterium glutamicum disclosed by the invention is an L-glutamine high-yieldstrain; compared with an unmodified strain, the strain has the advantages that the capacity of producing L-glutamine is enhanced, L-glutamine can be effectively accumulated, the yield of L-glutamine is increased, the conversion rate is relatively high, a foundation is laid for industrial production of L-glutamine, and the strain has a wide industrial application prospect.